Detalhe da pesquisa
1.
RRx-001, A novel dinitroazetidine radiosensitizer.
Invest New Drugs
; 34(3): 371-7, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26841903
2.
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Lancet Oncol
; 16(9): 1133-1142, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296952
3.
Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy.
Biochem Biophys Res Commun
; 447(3): 537-42, 2014 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24735538
4.
Locally administered heparin-binding epidermal growth factor-like growth factor reduces radiation-induced oral mucositis in mice.
Sci Rep
; 10(1): 17327, 2020 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33060741
5.
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo.
Mol Cancer Ther
; 7(6): 1569-78, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18566227
6.
A note on improved statistical approaches to account for pseudoprogression.
Cancer Chemother Pharmacol
; 81(3): 621-626, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29404682
7.
Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis.
Radiat Res
; 168(1): 125-33, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17722999
8.
Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia.
Cancer Res
; 65(1): 284-90, 2005 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15665305
9.
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Clin Epigenetics
; 9: 4, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28149332
10.
Alteration of Interneuron Immunoreactivity and Autophagic Activity in Rat Hippocampus after Single High-Dose Whole-Brain Irradiation.
Cureus
; 9(6): e1414, 2017 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28861331
11.
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Expert Opin Investig Drugs
; 26(1): 109-119, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27935336
12.
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma.
Int J Radiat Oncol Biol Phys
; 65(2): 493-8, 2006 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16563655
13.
Rockets, radiosensitizers, and RRx-001: an origin story part I.
Discov Med
; 21(115): 173-80, 2016 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27115167
14.
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
Oncotarget
; 6(41): 43172-81, 2015 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26657731
15.
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
Redox Biol
; 5: 422, 2015 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28162292
16.
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.
Oncotarget
; 6(25): 21547-56, 2015 Aug 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26280276
17.
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.
Redox Biol
; 6: 1-8, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26164533
18.
Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Int J Radiat Oncol Biol Phys
; 60(1): 197-203, 2004 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15337556
19.
A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
Int J Radiat Oncol Biol Phys
; 58(4): 1215-27, 2004 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15001266
20.
The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Radiat Res
; 157(1): 45-51, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11754641